Coeptis Therapeutics (Nasdaq: COEP), a Wexford, PA-based biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, closed on $4.3m in financing.
The round was led by led by CJC Investment Trust, an entity controlled by board member Christopher Calise. Under the terms of the financing, the Series A Preferred is convertible into shares of the Company’s common stock at a price of $0.40per share, subject to limitations. The investors also received in the aggregate a 6.45% equity interest in two of the Company’s newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.
The company intends to use the funds for the repayment of outstanding obligations, working capital, and general corporate purposes.
Led by Dave Mehalick, President and CEO, Coeptis Therapeutics Holdings, together with its subsidiaries including Coeptis Therapeutics, and Coeptis Pharmaceuticals, (collectively “Coeptis”), is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, it is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
Commenting on the news, Dave Mehalick said: “We are grateful for the continued support from our investors, particularly in these transformative times for Coeptis Therapeutics. These individuals share our passion and long-term vision for Coeptis, and their support goes beyond investment, reflecting a focus on the Company’s future.”
FinSMEs
20/06/2024